Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Edgewise Therapeutics Inc
(NQ:
EWTX
)
20.94
+1.22 (+6.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edgewise Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
August 08, 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Edgewise Therapeutics
Via
Business Wire
7 Small-Cap Stocks to Buy for Large-Scale Gains
July 30, 2024
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.
Via
InvestorPlace
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
July 23, 2024
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?
Via
Investor's Business Daily
Topics
Government
Exposures
Political
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
Edgewise Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
How Is The Market Feeling About Edgewise Therapeutics?
January 31, 2024
Via
Benzinga
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
May 13, 2024
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Via
Investor's Business Daily
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
May 10, 2024
From
Edgewise Therapeutics
Via
Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
May 09, 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 09, 2024
Via
Benzinga
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
May 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
May 06, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Insider Favorites: 7 Stocks with Bullish Buying Signals
February 11, 2024
Although you’ll still want to conduct your due diligence, following the smart money into these insider favorite stocks is tempting.
Via
InvestorPlace
Insiders Buying Edgewise Therapeutics And 2 Other Stocks
January 26, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
What's Going On With Edgewise Therapeutics Stock?
January 19, 2024
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.
Via
Benzinga
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday
January 19, 2024
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
January 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.